The number and the percentage of refused predictions are reported for cross-validation on the TS (containing 254 compounds). Each criterion is considered to be applied together with all the prior criteria.
(1) Chemicals without any neighbor with similarity ≥0.85 cannot be predicted.
(2) Chemicals with a single neighbor with similarity ≥0.85 but with similarity <0.90 cannot be predicted.
(3) Prediction is rejected if the difference among experimental values of nearest neighbors is greater than 1 log unit.
(4) If the nearest neighbor of a target chemical has an error in cross-validation greater than 1 log unit, the prediction of the target chemical is rejected.
Tab. S2: Performance of k-NN models
Statistics and predicted compounds are reported for both cross-validation on the TS (containing 254 compounds) and external validation on the VS (containing 179 compounds). Data relate to the maximum admitted difference between experimental values for the neighbors (Δ, see section 2.3) by 0.75 and 0.50 log units. 
Training set (TS)
Δ
2.8.Availability of information about the model:
Training set is available. Test set is under copyright and is not available.
2.9.Availability of another QMRF for exactly the same model:
None to date
3.1.Species:

Rattus norvegicus
3.2.Endpoint:
4. Human health effects 4.14 Repeated dose toxicity
3.3.Comment on endpoint:
Sub-chronic oral toxicity test: repeated dose 90-day oral (gavage, diet, drinking water) toxicity study in rodents [EC B.26, OECD 408]. .
3.4.Endpoint units:
mg/Kg body weight /day
3.5.Dependent variable:
logLO(A)EL
3.6.Experimental protocol:
The sub-chronic toxicity to rats was determined using the OECD 408 test
The experimental determination of LO(A)EL is closely dependent on the protocol employed. The test substance is administered daily at different doses to several groups of animals, one dose level per group, for a given period. During this period the animals are observed for signs
3.Defining the endpoint -OECD Principle 1
of toxicity. Then, the highest dose at which no adverse effects are noted (NO(A)EL) and the lowest dose at which an adverse effect is noted (LO(A)EL) are determined.
3.7.Endpoint data quality and variability:
The data were taken from three different databases When multiple data were available for the same compound, the lowest value has been retained.LO(A)EL data have not been extrapolated from a dose-response curve, and there is intrinsic uncertainty in the LO(A)EL experimental data that is related to the choose of administraton doses and dose spacing. The spacing differed even in the same experiment and did not always seem to follow any specific pattern.
4.1.Type of model:
k-Nearest Neighbor
4.2.Explicit algorithm:
k-Nearest Neighbor 2c. If the neighbor has at least one other similar compound within the training set, but it is not predicted because it not fulfill others conditions (e.g., differences among experimental values for its similar compounds), the query prediction is rejected.
5.2.Method used to assess the applicability domain:
The parameters have been choosed in order to obtain good performance in LOO internal cross-vaidation on the Training set.
5.3.Software name and version for applicability domain assessment:
Micorsoft To be entered by JRC
10.2.Publication date:
To be entered by JRC
10.3.Keywords:
10.4.Comments:
